Bajaj Healthcare Limited Receives Listing Approval for 20,79,409 Equity Shares Allotted via Warrant Conversion

Bajaj Healthcare Limited has received listing approvals from the National Stock Exchange of India Limited (NSE) and BSE Limited for 20,79,409 equity shares of face value ₹5/- each. The approvals, communicated on May 06, 2026, pertain to shares allotted pursuant to the exercise of options for the conversion of convertible warrants into equity shares on a preferential basis. The development was disclosed by the company in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Details of the Listing Approval

The following table summarises the key parameters of the approved listing:

Parameter: Details Number of Equity Shares: 20,79,409 Face Value: ₹5/- each Issue Premium: ₹333/- per share Distinctive Numbers: 31583253 to 33662661 Allottees: Promoters and Non-Promoters Basis of Allotment: Preferential basis via warrant conversion NSE Approval Reference: NSE/LIST/54371 BSE Approval Reference: LOD/PREF/RB/FIP/179/2026-27 Approval Date: May 06, 2026

Exchange Approvals and Conditions

NSE granted in-principle approval for the listing of the 20,79,409 equity shares, subject to confirmation from depositories NSDL and CDSL regarding the credit of beneficiaries' accounts. BSE similarly granted listing approval and noted that trading approval will be issued only after the company fulfils specific conditions.

The conditions stipulated by BSE for trading approval include:

Submission of listing approval from NSE (if applicable)

Confirmation letters from NSDL/CDSL confirming credit of the shares to respective beneficiary accounts and admission to the depository system

Confirmation letters from NSDL/CDSL regarding lock-in of pre-preferential holding (if applicable)

Regulatory Compliance Requirements

BSE further directed Bajaj Healthcare to ensure compliance with Regulation 167 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations. The exchange also noted that, as per Schedule XIX of the ICDR Regulations and SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, the company is required to make an application for trading approval to the stock exchanges within seven working days from the date of grant of listing approval. Non-compliance with this requirement will attract fines as specified in the aforementioned SEBI circular.

Additionally, BSE indicated that in the event of a change exceeding two per cent of the total paid-up share capital, the company shall file the shareholding pattern in XBRL mode as required under Regulation 31(1)(c) of the SEBI LODR Regulations, 2015. The intimation was signed by Monica Tanwar, Company Secretary and Compliance Officer of Bajaj Healthcare Limited, on May 07, 2026.

Bajaj Healthcare Limited has announced a board meeting scheduled for May 8, 2026, in compliance with Regulation 29 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will address key financial matters for the quarter and financial year ended March 31, 2026.

Board Meeting Agenda

The board of directors will convene to deliberate on two primary matters during the scheduled meeting:

Agenda Item Details Financial Results Consider and approve Audited Financial Results for Q4 and FY ended March 31, 2026 Dividend Recommendation Consider and recommend Final Dividend on Equity Shares for FY2025-26 Approval Requirement Subject to shareholder approval at the ensuing Annual General Meeting

Trading Window Restrictions

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, Bajaj Healthcare has implemented trading restrictions for insiders and designated persons. The trading window closure details are as follows:

Parameter Timeline Closure Period April 01, 2026 onwards Reopening 48 hours after declaration of audited financial results Applicable Persons All insiders, designated persons, and their immediate relatives Reference Notice Earlier notice dated March 24, 2026

Regulatory Compliance

The announcement, dated May 02, 2026, was formally communicated to both major stock exchanges where the company's shares are listed. The notification ensures compliance with regulatory requirements for timely disclosure of material information to stakeholders and the investment community.

The company secretary and compliance officer, Monica Tanwar, has signed the official communication, emphasizing the company's commitment to maintaining transparency and adhering to regulatory guidelines throughout the financial results declaration process.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.